---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-011698"
form_type: "8-K"
ticker: "IRMD"
cik: "0001325618"
company_name: "IRADIMED CORP"
filed_at: "2022-02-04T23:59:59+00:00"
generated_at: "2026-06-27T10:59:12.679434+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Q4 revenue up 39% YoY to $11.9M; guides FY22 rev $51.4-52.2M

## Summary
- Q4 2021 GAAP diluted EPS $0.31 vs $0.05 YoY; non-GAAP diluted EPS $0.33 vs $0.07.
- Full-year 2021 revenue $41.8M (+32% YoY); full-year GAAP EPS $0.74 vs $0.11.
- Gross profit margin improved to 77.9% in Q4 vs 75.3% YoY; free cash flow $10.8M for FY.
- FY2022 guidance: revenue $51.4M-$52.2M, GAAP EPS $0.82-$0.90; Q1 rev $12.1M-$12.3M.
- Record bookings growth: Q4 bookings +48% YoY, FY bookings +39% YoY, signaling strong demand.

## SEC filing metadata
- accession: 0001104659-22-011698
- form_type: 8-K
- ticker: IRMD
- cik: 0001325618
- company_name: IRADIMED CORP
- filed_at: 2022-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1325618/000110465922011698/0001104659-22-011698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1325618/000110465922011698/tm225491d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-011698
- JSON: https://secwatch.observer/filing/0001104659-22-011698.json
- Plain text: https://secwatch.observer/filing/0001104659-22-011698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.